Literature DB >> 22457230

Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure.

Ravichandran Ramasamy1, Ann Marie Schmidt.   

Abstract

The receptor for advanced glycation end products (RAGE) is expressed in the heart in cardiomyocytes, vascular cells, fibroblasts, and in infiltrating inflammatory cells. Experiments in murine, rat, and swine models of injury suggest that RAGE and the ligands of RAGE are upregulated in key injuries to the heart, including ischemia/reperfusion injury, diabetes, and inflammation. Pharmacological antagonism of RAGE or genetic deletion of the receptor in mice is strikingly protective in models of these stresses. Data emerging from human studies suggest that measurement of levels of RAGE ligands or soluble RAGEs in plasma or serum may correlate with the degree of heart failure. Taken together, the ligand-RAGE axis is implicated in heart failure and we predict that therapeutic antagonism of RAGE might be a unique target for therapeutic intervention in this disorder.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22457230      PMCID： PMC4500111          DOI： 10.1007/s11897-012-0089-5

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  71 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

2.  Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE.

Authors:  Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Lilian Grigorian-Shamagian; María Moure-González; Ana Seoane-Blanco; Alfonso Varela-Román; Ezequiel Alvarez; José R González-Juanatey
Journal:  Eur J Heart Fail       Date:  2010-08-03       Impact factor: 15.534

3.  HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction.

Authors:  M Andrassy; H C Volz; N Riedle; G Gitsioudis; C Seidel; D Laohachewin; A R Zankl; Z Kaya; A Bierhaus; E Giannitsis; H A Katus; G Korosoglou
Journal:  J Intern Med       Date:  2011-03-28       Impact factor: 8.989

4.  Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Authors:  Colomba Falcone; Enzo Emanuele; Angela D'Angelo; Maria P Buzzi; Chiara Belvito; Mariaclara Cuccia; Diego Geroldi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

5.  Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients.

Authors:  Fernanda I Staquicini; Marina Cardó-Vila; Mikhail G Kolonin; Martin Trepel; Julianna K Edwards; Diana N Nunes; Anna Sergeeva; Eleni Efstathiou; Jessica Sun; Nalvo F Almeida; Shi-Ming Tu; Gregory H Botz; Michael J Wallace; David J O'Connell; Stan Krajewski; Jeffrey E Gershenwald; Jeffrey J Molldrem; Anne L Flamm; Erkki Koivunen; Rebecca D Pentz; Emmanuel Dias-Neto; João C Setubal; Dolores J Cahill; Patricia Troncoso; Kim-Ahn Do; Christopher J Logothetis; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-02       Impact factor: 11.205

6.  Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.

Authors:  Evis Harja; De-xiu Bu; Barry I Hudson; Jong Sun Chang; Xiaoping Shen; Kellie Hallam; Anastasia Z Kalea; Yan Lu; Rosa H Rosario; Sai Oruganti; Zana Nikolla; Dmitri Belov; Evanthia Lalla; Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

7.  RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response.

Authors:  M A Hofmann; S Drury; B I Hudson; M R Gleason; W Qu; Y Lu; E Lalla; S Chitnis; J Monteiro; M H Stickland; L G Bucciarelli; B Moser; G Moxley; S Itescu; P J Grant; P K Gregersen; D M Stern; A M Schmidt
Journal:  Genes Immun       Date:  2002-05       Impact factor: 2.676

8.  Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice.

Authors:  Jan M Nielsen; Steen B Kristiansen; Rikke Nørregaard; Claus L Andersen; Larry Denner; Torsten T Nielsen; Allan Flyvbjerg; Hans E Bøtker
Journal:  Eur J Heart Fail       Date:  2009-06-05       Impact factor: 15.534

9.  RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model.

Authors:  Alexey Aleshin; Radha Ananthakrishnan; Qing Li; Rosa Rosario; Yan Lu; Wu Qu; Fei Song; Soliman Bakr; Matthias Szabolcs; Vivette D'Agati; Rui Liu; Shunichi Homma; Ann Marie Schmidt; Shi Fang Yan; Ravichandran Ramasamy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-02-01       Impact factor: 4.733

10.  Formin follows function: a muscle-specific isoform of FHOD3 is regulated by CK2 phosphorylation and promotes myofibril maintenance.

Authors:  Thomas Iskratsch; Stephan Lange; Joseph Dwyer; Ay Lin Kho; Cris dos Remedios; Elisabeth Ehler
Journal:  J Cell Biol       Date:  2010-12-13       Impact factor: 10.539
View more
  20 in total

Review 1.  Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.

Authors:  Remi Neviere; Yichi Yu; Lei Wang; Frederic Tessier; Eric Boulanger
Journal:  Glycoconj J       Date:  2016-06-08       Impact factor: 2.916

Review 2.  RAGE and glyoxalase in kidney disease.

Authors:  Reiko Inagi
Journal:  Glycoconj J       Date:  2016-06-06       Impact factor: 2.916

Review 3.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

4.  Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease.

Authors:  Abdullah Sarkar; Kailash Prasad; Bulat A Ziganshin; John A Elefteriades
Journal:  Aorta (Stamford)       Date:  2013-08-01

Review 5.  Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities.

Authors:  Michele Cavalera; Junhong Wang; Nikolaos G Frangogiannis
Journal:  Transl Res       Date:  2014-05-10       Impact factor: 7.012

6.  Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study.

Authors:  Mariana Lazo; Marc K Halushka; Lu Shen; Nisa Maruthur; Casey M Rebholz; Andreea M Rawlings; Ron C Hoogeveen; Tina E Brinkley; Christie M Ballantyne; Brad C Astor; Elizabeth Selvin
Journal:  Am Heart J       Date:  2015-08-14       Impact factor: 4.749

Review 7.  Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.

Authors:  Magdalena Pertynska-Marczewska; Zaher Merhi
Journal:  Reprod Sci       Date:  2014-09-16       Impact factor: 3.060

Review 8.  The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease.

Authors:  Ravichandran Ramasamy; Alexander Shekhtman; Ann Marie Schmidt
Journal:  Expert Opin Ther Targets       Date:  2015-11-11       Impact factor: 6.902

9.  Women with Type 1 diabetes (T1D) experience a shorter reproductive period compared with nondiabetic women: the Pittsburgh Epidemiology of Diabetes Complications (EDC) study and the Study of Women's Health Across the Nation (SWAN).

Authors:  Yan Yi; Samar R El Khoudary; Jeanine M Buchanich; Rachel G Miller; Debra Rubinstein; Karen Matthews; Trevor J Orchard; Tina Costacou
Journal:  Menopause       Date:  2021-03-01       Impact factor: 3.310

10.  The skin landscape in diabetes mellitus. Focus on dermocosmetic management.

Authors:  Gérald E Piérard; Sophie Seité; Trinh Hermanns-Lê; Philippe Delvenne; André Scheen; Claudine Piérard-Franchimont
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.